Annals of Oncology Advance Access originally published online on August 25, 2006
Annals of Oncology 2006 17(11):1637-1643; doi:10.1093/annonc/mdl177
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2006 European Society for Medical Oncology
breast cancer |
Clinical outcomes of ethnic minority women in MA.17: a trial of letrozole after 5 years of tamoxifen in postmenopausal women with early stage breast cancer
1 Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
2 National Cancer Institute of Canada Clinical Trials Group, Kingston, ONT, Canada
3 Mayo Clinic, Rochester, MN, USA
4 McMaster University, Hamilton, ONT, Canada
* Correspondence to: Dr B. Moy, MPH, Massachusetts General Hospital, Gillette Center for Women's Cancers, 55 Fruit Street, YAW 9A, Boston, MA 02114, USA. Tel: +1 (617) 724-6975; Fax: +1 (617) 724-3166. E-mail: bmoy{at}partners.org
Background: Aromatase inhibitors are widely employed in the adjuvant treatment of early stage breast cancer. The impact of aromatase inhibitors has not been established in ethnic minority women.
Patients and methods: The purpose of this study was to evaluate the impact of letrozole on minority women in MA.17, a placebo-controlled trial of letrozole following 5 years of tamoxifen in postmenopausal women with early stage breast cancer. Retrospective comparison of disease-free survival (DFS), side effects, and mean changes in quality of life (QOL) scores from baseline between Caucasian and minority women was performed.
Results: Minority (n = 352) and Caucasian (n = 4708) women were analyzed. There was no difference between these groups in DFS (91.6% versus 92.4% respectively for 4 year DFS). Letrozole, compared with placebo, significantly improved DFS for Caucasians (HR = 0.55; P < 0.0001) but not for minorities (HR = 1.39; P = 0.53). Among women who received letrozole, minorities had a significantly lower incidence of hot flashes (49% versus 58%; P = 0.02), fatigue (29% versus 39%; P = 0.005), and arthritis (2% versus 7%; P = 0.006) compared with Caucasians. Mean change in QOL scores for minority women who received letrozole demonstrated improved mental health at the 6-month assessment (P = 0.02) and less bodily pain at the 12-month assessment (P = 0.046).
Conclusion: Letrozole improved DFS in Caucasians but a definite benefit in minority women has not yet been demonstrated. Minority women tolerated letrozole better than Caucasians in terms of toxicity. These results need confirmation in other trials of aromatase inhibitors.
Key words: early breast cancer, aromatase inhibitors, minority race, ethnicity
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. N. Ingle, D. Tu, J. L. Pater, H. B. Muss, S. Martino, N. J. Robert, M. J. Piccart, M. Castiglione, L. E. Shepherd, K. I. Pritchard, et al. Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17 Ann. Onc., May 1, 2008; 19(5): 877 - 882. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. U. Lin and E. P. Winer Optimal Use of Aromatase Inhibitors: To Lead or to Follow? J. Clin. Oncol., July 1, 2007; 25(19): 2639 - 2641. [Full Text] [PDF]
|
|